TriSalus Life Sciences (TLSI)

Executive Summary

TriSalus Life Sciences is a clinical-stage oncology company focused on transforming outcomes for patients with solid tumors through its proprietary Pressure-Enabled Drug Delivery (PEDD) technology and investigational immunotherapy, SD-101. The company's platform addresses key limitations of conventional drug delivery in solid tumors, such as elevated intratumoral pressure and poor perfusion, by enabling more uniform distribution and higher concentrations of therapeutics. SD-101, a Toll-like receptor 9 agonist, is being evaluated in combination with standard-of-care therapies for liver tumors, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma. TriSalus's approach aims to reprogram the tumor microenvironment to enhance anti-tumor immune responses. The company is publicly traded under ticker TLSI with a valuation of approximately $266 million and is headquartered in Westminster, Colorado.

Upcoming Catalysts (preview)

• H2 2026Phase 2 data readout for SD-101 in hepatocellular carcinoma40% success
• H1 2026FDA meeting to discuss pivotal trial design for SD-10160% success
• TBDPotential partnership for PEDD technology with larger biopharma30% success